The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 19, 2012
Filed:
May. 15, 2003
Susann Schweiger, Berlin, DE;
Hans-hilger Ropers, Berlin, DE;
Jennifer Winter, Berlin, DE;
Sybille Krauss, Berlin, DE;
Vanessa Suckow, Berlin, DE;
Rainer Schneider, Wörgl, AT;
Alexander Trockenbacher, Innsbruck, AT;
John Foerster, Berlin, DE;
Susann Schweiger, Berlin, DE;
Hans-Hilger Ropers, Berlin, DE;
Jennifer Winter, Berlin, DE;
Sybille Krauss, Berlin, DE;
Vanessa Suckow, Berlin, DE;
Rainer Schneider, Wörgl, AT;
Alexander Trockenbacher, Innsbruck, AT;
John Foerster, Berlin, DE;
Abstract
The present invention relates to a method of preventing or treating a disease correlated with or caused by non-physiologically increased intracellular levels of the catalytic subunit of microtubule-associated protein phosphatase 2A (PP2Ac) comprising administering to a subject affected by said disease or in danger of developing said disease a pharmaceutically effective amount of a protein selected from the group of MID1 or MID2 or a nucleic acid encoding said protein. The invention further relates to a method of preventing or treating a disease correlated with or caused by non-physiologically decreased intracellular levels of the catalytic subunit of microtubule-associated protein phosphatase 2A (PP2Ac) comprising administering to a subject affected by said disease or in danger of developing said disease a pharmaceutically effective amount of a peptidic fragment of MID1 or MID2 wherein said peptidic fragment comprises amino acids 108-165 (preferably 110-165) of MID1, amino acids 108-165 (preferably 110-165) of MID2 or with an effective amount of a fragment of PP2Ac wherein said fragment comprises the binding site to a4 or of a peptide fragment of a4 comprising amino acids 236-279 or with an effective amount of a nucleic acid molecule encoding said peptide fragment or with an effective amount of a molecule interfering with the interaction of MID1 with a4 or with an effective amount of a molecule interfering with the expression or activity of MID1 and/or a 4.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile